Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.
Dr Tim MitchellCEO
Dr John ReaderCSO
Summit Therapeutics plc
We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.
Our strategy focuses on two therapy areas: Duchenne muscular dystrophy, a fatal genetic muscle wasting disease, and the infectious disease caused by the bacteria C. difficile.
Dr Richard PyeSenior Director, Corporate Affairs
Dr Daniel ElgerSenior Vice President of Research & Development, Chief Commercial Officer
Dr Kevin PongVice President, Business Development and Licensing
Sygnature Discovery Ltd
Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise. Founded in 2004, Sygnature undertakes complete drug discovery programmes and target validation, hit identification, hit-to-lead and lead optimisation projects for pharmaceutical and biotech companies. Core capabilities include medicinal and synthetic chemistry, in vitro biology/screening, computational chemistry, DMPK and protein crystallography. Sygnature has an enviable track record of success in delivering multiple clinical candidates.
Winner of OBN Best Synthetic Biology Company Award.
Dr Simon HirstCEO
Dr Paul ClewlowSenior Vice President Business Development
SYNthesis med chem is a chemistry-focussed contract research organisation that carries out custom synthesis, medicinal chemistry and integrated drug discovery projects for biotech & pharma companies and research institutes. In addition to providing chemistry services, SYNthesis also establishes shared risk collaborations with partners, the goal being to identify, develop and partner small molecule drugs.
Mr Simon BuryGlobal Head of Business Development
Prof Andrew WilksChairman
TranScrip supports the development and lifecycle management of biopharmaceutical products. We provide expertise, resourcing and strategic oversight from translational medicine to successful registration and market access.